On July 16, 2015 Navidea Biopharmaceuticals reported the results of voting at its 2015 Annual Meeting of Stockholders (the Annual Meeting) held July 16, 2015 (Press release, Navidea Biopharmaceuticals, JUL 16, 2015, View Source;p=RssLanding&cat=news&id=2068607 [SID:1234506354]). Approximately 80 percent of outstanding shares were represented at the meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the Annual Meeting, Navidea’s stockholders:

Elected Gordon A. Troup to the Navidea Board of Directors to serve for a term of three years; and
Ratified the appointment of BDO USA, LLP to act as the Company’s independent registered public accounting firm for 2015.
The final results are subject to verification by the independent election inspectors and will be reported in a Form 8-K to be filed by Navidea with the Securities and Exchange Commission in the next few days.

Following the formal business portion of the Annual Meeting, Rick Gonzalez, Navidea President and CEO, made a brief presentation to stockholders in attendance at the Annual Meeting, including overviews on the following:

Lymphoseek (technetium Tc-99m tilmanocept) injection U.S. commercialization and life cycle management activities; and
Manocept CD206 targeting platform update, including a discussion of Macrophage Therapeutics development activities.